Oppenheimer Maintains Outperform On Macrocure, Sees 150% Upside
In a research report released Tuesday, Oppenheimer analyst Steven Lichtman maintained an Outperform rating on Macrocure Ltd. (NASDAQ:MCUR) with a price target of $20.00, which represents a potential upside of 150% from where the stock is currently trading.
Lichtman said, “MCUR’s Phase 3 trials continued to show progress in 3Q, with its DFU pivotal trial completing enrollment in September and the VLU trial continuing recruitment with 25+ operational clinical sites in the US. Timing of previous milestones was maintained (Exhibit 2), with completion of the Mechanism of Action (MOA) study expected in 4Q. Management also reported that the FDA has removed its blood- matching requirement, which should increase the commercial scalability of CureXcell post-approval.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Steven Lichtman has a total average return of 2.8% and a 56.7% success rate. Lichtman is ranked #1507 out of 3363 analysts.